1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional) is sponsored by Agency for Healthcare Research and Quality (AHRQ) and National Institutes of Health (NIH). This program supports the development and implementation of digital tools that enhance healthcare quality, safety, and efficiency.
It aims to accelerate the integration of technology into real-world healthcare settings, empowering researchers, providers, and innovators to improve patient outcomes through data-driven care, AI-based decision support, and smart clinical workflows. The R21/R33 mechanism is designed to support early-stage research (R21) and translational development (R33), bridging the gap between innovation and clinical adoption.
Get alerted about grants like this
Get emailed when new opportunities from “Agency for Healthcare Research and Quality (AHRQ) and National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S.-based public or non-profit institutions. For-profit organizations can participate as subawardees or consortium partners. Small businesses are eligible. Confirm the full requirements in the official notice before applying.
The current listing shows R21 Phase: up to $275,000/2 years; R33 Phase: up to $1,000,000/3 years; maximum project period of 5 years total. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional) is funded by Agency for Healthcare Research and Quality (AHRQ) and National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
Despite NIH budget pressure, hundreds of millions in AI healthcare research grants remain active in 2026. Full breakdown of Bridge2AI, AHRQ patient safety, NSF/NIH Smart Health, BARDA, Gates Foundation, and Google.org — with eligibility, amounts, and current deadlines.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read article